A series of new images reveals the most detailed glimpse yet at Fyodor, the Russian spacebot bound for the International Space Station. The humanoid robot lift weights, and can drive a car.
Read more
The effects or Inflammation and the effect it has on the immune system are discussed in this article at FightAging!
With age, the immune system falls into a state of ever increasing chronic inflammation, a process known as inflammaging: the immune system is overactive, but nonetheless declines in effectiveness at the same time. Researchers here consider how inflammaging can damage the bone marrow stem cell populations responsible for generating immune cells, possibly the basis for a vicious cycle in which the failures of the immune system feed upon themselves to accelerate age-related damage and dysfunction.
Hematopoiesis is an active, continuous process involving the production and consumption of mature blood cells that constitute the hemato-lymphoid system. All blood cells arise from a small population of hematopoietic stem cells (HSCs) in the bone marrow (BM) that have two unique properties: self-renewing capacity, the ability to generate themselves, and multi-lineage differentiation capacity, the ability to produce all blood cell types. Since, in the steady state, most adult HSCs are in the G0 phase of the cell cycle, i.e., they are quiescent and are estimated to turnover slowly on a monthly time scale, daily hematopoietic production is mainly sustained by highly proliferative downstream hematopoietic progenitor cells (HPCs).
Aging of the hematopoietic system is represented by functional declines in both the adaptive and the innate immune system, an immunosenescence that leads to high susceptibility to infections, low efficacy of vaccinations, and increased vulnerability to the development of autoimmunity and hematologic malignancies. It has been show that (a) B cell production decreases significantly with advancing age, i.e., the naive B cell pool diminishes, while the memory B cell pool expands. Diversity of the B cell repertoire also decreases in association with lowered antibody affinity and impaired class switching. B cells are prone to produce auto-antibodies increasing the incidence of spontaneous autoimmunity; (b) de novo T cell production also declines with aging partially due to thymic involution.
Read more
John Glenn, who captured the nation’s attention in 1962 as the first American to orbit the Earth during a tense time when the United States sought supremacy over the Soviet Union in the space race, and who rocketed back into space 36 years later, becoming the oldest astronaut in history, died Dec. 8 at a hospital in Columbus, Ohio. Mr. Glenn, who in his post-NASA career served four terms as a U.S. senator from Ohio, was 95.
The death was confirmed by Hank Wilson, communications director at the John Glenn College of Public Affairs at Ohio State University. Mr. Glenn had a stroke after heart-valve replacement surgery in 2014, but the immediate cause was not announced.
Mr. Glenn was one of the seven original astronauts in NASA’s Mercury program, which was a conspicuous symbol of the country’s military and technological might at the height of the Cold War. He was not the first American in space — two of his fellow astronauts preceded him — but his three-orbit circumnavigation of the globe captured the imagination of his countrymen like few events before or since. Mr. Glenn was the last survivor of the Mercury Seven.
Read more
Artificial blood takes a big step forward!
(HealthDay)—Artificial blood stored as a powder could one day revolutionize emergency medicine and provide trauma victims a better chance of survival.
Researchers have created an artificial red blood cell that effectively picks up oxygen in the lungs and delivers it to tissues throughout the body.
This artificial blood can be freeze-dried, making it easier for combat medics and paramedics to keep on hand for emergencies, said senior researcher Dr. Allan Doctor. He is a critical care specialist at Washington University School of Medicine in St. Louis.
Nantero Inc., the nanotechnology company developing next-generation memory using carbon nanotubes, today announced the closing of an over $21 million financing round. The lead investor in the round was Globespan Capital Partners and also included participation from both new and existing strategic and financial investors. Nantero currently has more than a dozen partners and customers in the consumer electronics, enterprise systems, and semiconductor industries actively working on NRAM®. The new funding will enable the company to support these partners in bringing multiple products into the market, while also enabling new customers to begin development. This financing round brings the total invested in Nantero to date to over $110 million.
“This round enables Nantero to accelerate its pace in product development, especially of its multi-gigabyte DDR4-compatible memory product,” said David Poltack, Managing Director, Globespan Capital Partners. “Nantero has multiple industry-leading customers who would like to receive NRAM even sooner. The fact that several of these customers, as well as key partners in the ecosystem, have decided to also invest in Nantero is a strong sign of confidence given how well they know Nantero and its product from years of working together.”
“The customer traction we’ve achieved at Nantero has been overwhelming, as evidenced by our recent announcement that NRAM had been selected by both Fujitsu Semiconductor and Mie Fujitsu Semiconductor,” said Greg Schmergel, Co-Founder & CEO of Nantero. “With this additional funding, we will be able to help these existing customers speed their time to market while also supporting the many other companies that have approached us about using Nantero NRAM in their next generation products.”
Read more
Senolytics meets Synthetic biology so come along and ask them anything!
Hey folks, We are excited to announce that the CellAge longform AMA opens Friday for questions and the CellAge team will answer them from Monday 11am PST/2pm EST/6pm GMT. We will update the link to the Futurology AMA once it is ready.
CellAge are using synthetic biology to create new biomarkers for senescent cell detection, developing a new therapy to remove senescent cells which drive the aging process using custom synthetic biology. Come along and ask them all about it.
Israel’s Bonus says lab-grown bones successfully transplanted. Jim Drury reports.
A lab-grown, semi-liquid bone graft has been successfully injected into 11 patients’ jaws to repair bone loss. Israeli biotech firm Bonus Biogroup announced the early stage clinical trial results on Monday. SOUNDBITE (English) ORA BURGER, VICE PRESIDENT OF REGULATION AFFAIRS AT BONUS BIOGROUP, SAYING: “What we are announcing to the world is that real success in our clinical study in regenerating new bone in maxillofacial site in the jaws, it was 100 percent successful in all 11 patients.” The injectable bone grafts are made in the company’s Haifa plant, using cells extracted from patients’ fat tissue. They’re grown in sterile clean rooms, on biodegradable 3D scaffolds, before being injected into the voids in the jawbones.
Read more